System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 40631440 DOI: 10.1002/alz.70463

Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease.

Alzheimers Dement 21(7):e70463

Authors: Alexandra Gogola, Xuemei Zeng, Lilcelia A Williams, Theresa Chapple-McGruder, Anum Saeed, Brian J Lopresti, Beth Snitz, Dana Tudorascu, Davneet Minhas, Milos D Ikonomovic, Julia Kofler, Cristy Matan, Tharick A Pascoal, Howard Aizenstein, Henrik Zetterberg, Kaj Blennow, Oscar Lopez, Victor L Villemagne, Thomas K Karikari, Ann D Cohen

Affiliations

  • Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
  • Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
  • UK Dementia Research Institute at UCL, London, UK.
  • Hong Kong Center for Neurodegenerative Diseases, InnoHK, Hong Kong, China.
  • Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.

Abstract

INTRODUCTION

Given the predominance of imaging and plasma biomarkers in Alzheimer's disease observational studies and clinical trials, it is critical to understand the differences between these biomarkers across racialized groups.

METHODS

A total of 260 older adults without dementia racialized as Black and/or African American (AA) and non-Hispanic white (NHW), ranging in age from 50 to 90 years (68.8 ± 9.1 years), were evaluated for differences in plasma amyloid-β (Aβ) 42/Aβ40, p-tau181, p-tau217, p-tau231, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) as well as Aβ positron emission tomography (PET) and magnetic resonance (MR) imaging-derived cortical thickness using Mann-Whitney U tests and analysis of covariance (ANCOVA).

RESULTS

Both Mann-Whitney tests and ANCOVA found significant differences between groups racialized as AA or NWH with respect to global 11[C]-Pittsburgh Compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness values, p-tau181, and p-tau231 values (p < 0.05).

DISCUSSION

Racialization should be given more consideration in AD clinical research, particularly when biomarker results are used for inclusion or exclusion criteria for clinical trials and qualification in clinical practice.

HIGHLIGHTS

Global 11[C]-Pittsburgh compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness, p-tau181, and p-tau231 differed between groups Differences were unaffected by age, sex, apolipoprotein E *4 (APOE*4), education, and Mini-Mental State Examination (MMSE) score Racialization needs more consideration in Alzheimer's disease clinical research Additional work is needed to understand the sources of biomarker differences.

MeSH

Dementia, Neuroimaging, Alzheimer Disease, Biomedical Research, Biomarkers, Research, Plasma

Cited by